IP Library Granted Patent US 10,030,242
Granted Patent B2
US 10,030,242 · App. 13/697,206 · Granted Jul 24, 2018

Bioactive renal cells

Inventors: Timothy A. Bertram (George Town, KY); Roger M. Ilagan (Burlington, NC); Russell W. Kelley (Winston-Salem, NC); Sharon C. Presnell (Lewisville, NC); Sumana Choudhury (Kernersville, NC); Andrew T. Bruce (Lexington, NC); Christopher W. Genheimer (Colfax, NC); Bryan R. Cox (Winston-Salem, NC); Kelly I. Guthrie (Winston-Salem, NC); Joydeep Basu (Winston-Salem, NC); Shay M. Wallace (Winston-Salem, NC); Eric Werdin (Lewisville, TX); Oluwatoyin A. Knight (Winston-Salem, NC); Namrata D. Sangha (Winston-Salem, NC); John W. Ludlow (Carrboro, NC); Craig R. Halberstadt (Clemmons, NC); Richard Payne (Winston-Salem, NC); Neil F. Robins (Winston-Salem, NC); Darell McCoy (Clemmons, NC); Deepak Jain (Winston-Salem, NC); Manuel J. Jayo (Winston-Salem, NC); Elias A. Rivera (Oak Ridge, NC); Thomas Spencer (Winston-Salem, NC); Benjamin Watts (King, NC)
Assignee: InRegen
C12N15/113C12N5/0686C12Q1/6883C12N2310/141C12N2320/30C12N2320/32C12Q2600/106C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,030,242
App. No.
13/697,206
Granted
Jul 24, 2018
Kind
B2
Abstract

The present invention concerns bioactive renal cell populations, renal cell constructs, and methods of making and using the same.

Claims (17)

1. A method of providing a regenerative effect to a native kidney comprising in vivo contacting the native kidney with a composition comprising human secreted vesicles produced by an enriched renal cell population, wherein the vesicles comprise exosomes comprising a secreted paracrine factor that attenuates Plasminogen Activation Inhibitor-1 (PAI-1) signaling and/or Transforming Growth Factor Beta (TGFβ) signaling, and wherein the regenerative effect is a reduction in renal fibrosis.

2. The method of claim 1 , wherein the paracrine factor inhibits Plasminogen Activation Inhibitor-1 (PAI-1).

3. The method of claim 1 , wherein the paracrine factor is an miRNA.

4. The method of claim 1 , wherein the paracrine factor is an miRNA that inhibits Plasminogen Activation Inhibitor-1 (PAI-1).

5. The method of claim 3 , wherein the miRNA is extra-vesicular.

6. The method of claim 1 wherein the products are secreted from a renal cell construct comprising an enriched renal cell population directly seeded on or in a scaffold.

7. The method of claim 6 wherein the scaffold comprises a biocompatible material.

8. The method of claim 7 wherein the biocompatible material is a hydrogel.

9. The method of claim 8 wherein the hydrogel is gelatin.

10. The method of claim 1 wherein the regenerative effect is a reduction in epithelial-mesenchymal transition (EMT).

11. The method of claim 1 wherein the population comprises a first cell population, B2, comprising an enriched population of tubular cells having a density between about 1.045 g/mL and about 1.052 g/mL.

12. The method of claim 1 wherein the population comprises an admixture of human renal cells comprising a first cell population, B2, and a second cell population, wherein B2 comprises an enriched population of tubular cells having a density between about 1.045 g/mL and about 1.052 g/mL and wherein the second cell population comprises a B4 cell population having a density between about 1.063 g/mL and about 1.091 g/mL or a B3 cell population having a density between about 1.052 g ml and about 1.063 g/ml.

13. The method of claim 12 wherein the second cell population is a B4 cell population having a density between about 1.063 g/mL and about 1.091 g/mL.

14. The method of claim 12 wherein the second cell population is a B3 cell population having a density between about 1.052 g ml and about 1.063 g/ml.

15. The method of claim 13 wherein the admixture further comprises a third cell population, wherein the third cell population comprises a B3 cell population having a density between about 1.052 g ml and about 1.063 g/ml.

16. The method of claim 1 wherein the enriched renal cell population is non-autologous to the native kidney.

17. The method of claim 1 wherein the enriched renal cell population is autologous to the native kidney.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: BERTRAM, TIMOTHY A.
To: INREGEN
Reel/Frame 067601/0467 →
CHANGE OF NAME Recorded Aug 18, 2021
From: INREGEN
To: PROKIDNEY
Reel/Frame 057210/0820 →
CHANGE OF NAME Recorded Jul 10, 2017
From: REGENMED (CAYMAN) LTD.
To: INREGEN
Reel/Frame 043136/0545 →
MERGER AND CHANGE OF NAME Recorded Aug 2, 2016
From: REGENMEDTX, LLC; REGENMED (CAYMAN) LTD.
To: REGENMED (CAYMAN) LTD.
Reel/Frame 039550/0136 →
CHANGE OF OWNERSHIP Recorded Nov 11, 2015
From: TENGION, INC.
To: REGENMEDTX, LLC
Reel/Frame 037098/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2013
From: ILAGAN, ROGER M.; KELLEY, RUSSELL W.; PRESNELL, SHARON C.; CHOUDHURY, SUMANA; BRUCE, ANDREW T.; GENHEIMER, CHRISTOPHER W.; COX, BRYAN R.; GUTHRIE, KELLY I.; BASU, JOYDEEP; WALLACE, SHAY M.; WERDIN, ERIC S.; KNIGHT, OLUWATOYIN A.; SANGHA, NAMRATA D.; LUDLOW, JOHN W.; HALBERSTADT, CRAIG R.; PAYNE, RICHARD; ROBBINS, NEIL F.; MCCOY, DARELL; JAIN, DEEPAK; JAYO, MANEL J.; RIVERA, ELIAS A.; SPENCER, THOMAS; WATTS, BENJAMIN
To: TENGION, INC.
Reel/Frame 030693/0673 →
Continuity (11)
Provisional Application 61473111 · Apr 7, 2011
Provisional Application 61441423 · Feb 10, 2011
Provisional Application 61412933 · Nov 12, 2010
Provisional Application 61413382 · Nov 12, 2010
Provisional Application 61388765 · Oct 1, 2010
Provisional Application 61376586 · Aug 24, 2010
Provisional Application 61372077 · Aug 9, 2010
Provisional Application 61371888 · Aug 9, 2010
Provisional Application 61353895 · Jun 11, 2010
Provisional Application 61334032 · May 12, 2010
Related Publication 20160244751A1 · Aug 25, 2016